GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » Gross Profit

EirGenix (ROCO:6589) Gross Profit : NT$219 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is EirGenix Gross Profit?

EirGenix's gross profit for the three months ended in Dec. 2024 was NT$100 Mil. EirGenix's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was NT$219 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. EirGenix's gross profit for the three months ended in Dec. 2024 was NT$100 Mil. EirGenix's Revenue for the three months ended in Dec. 2024 was NT$295 Mil. Therefore, EirGenix's Gross Margin % for the quarter that ended in Dec. 2024 was 33.97%.

EirGenix had a gross margin of 33.97% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 12 years, the highest Gross Margin % of EirGenix was 70.04%. The lowest was 7.22%. And the median was 36.54%.

Warning Sign:

EirGenix Inc gross margin has been in long-term decline. The average rate of decline per year is -20.6%.


EirGenix Gross Profit Historical Data

The historical data trend for EirGenix's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EirGenix Gross Profit Chart

EirGenix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 750.67 1,093.05 756.45 236.74 218.99

EirGenix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.44 17.89 22.22 78.79 100.09

Competitive Comparison of EirGenix's Gross Profit

For the Biotechnology subindustry, EirGenix's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EirGenix's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EirGenix's Gross Profit distribution charts can be found below:

* The bar in red indicates where EirGenix's Gross Profit falls into.


;
;

EirGenix Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

EirGenix's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=1008.96 - 789.975
=219

EirGenix's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=294.641 - 194.555
=100

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$219 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

EirGenix's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=100 / 294.641
=33.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


EirGenix  (ROCO:6589) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

EirGenix had a gross margin of 33.97% for the quarter that ended in Dec. 2024 => Competition eroding margins


EirGenix Gross Profit Related Terms

Thank you for viewing the detailed overview of EirGenix's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


EirGenix Business Description

Traded in Other Exchanges
N/A
Address
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.

EirGenix Headlines

No Headlines